4//SEC Filing
Tommasi Ruben 4
Accession 0001104659-22-023787
CIK 0001724344other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 4:05 PM ET
Size
24.4 KB
Accession
0001104659-22-023787
Insider Transaction Report
Form 4
Tommasi Ruben
Chief Scientific Officer
Transactions
- Disposition to Issuer
Employee Stock Option (Right to Buy)
2021-07-16−22,816→ 0 totalExercise: $4.98Exp: 2025-08-11→ Common Stock (22,816 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2021-07-16−15,632→ 0 totalExercise: $6.85Exp: 2028-04-30→ Common Stock (15,632 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2021-07-16−50,411→ 0 totalExercise: $15.00Exp: 2028-09-24→ Common Stock (50,411 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2021-07-16−56,500→ 0 totalExercise: $5.66Exp: 2029-01-17→ Common Stock (56,500 underlying) - Award
Employee Stock Option (Right to Buy)
2021-07-16+15,210→ 15,210 totalExercise: $2.44Exp: 2031-07-15→ Common Stock (15,210 underlying) - Award
Employee Stock Option (Right to Buy)
2021-07-16+28,006→ 28,006 totalExercise: $2.44Exp: 2031-07-15→ Common Stock (28,006 underlying) - Award
Employee Stock Option (Right to Buy)
2021-07-16+43,460→ 43,460 totalExercise: $2.44Exp: 2031-07-15→ Common Stock (43,460 underlying) - Award
Employee Stock Option (Right to Buy)
2021-07-16+12,024→ 12,024 totalExercise: $2.44Exp: 2031-07-15→ Common Stock (12,024 underlying)
Footnotes (12)
- [F1]The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option will vest on May 13, 2016, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to Reporting Person continuing to provide service through each such date.
- [F10]The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option shall vest on January 1, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
- [F11]On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 56,500 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 43,460 shares of issuer's common stock, having an exercise price of $2.44 per share.
- [F12]Eighty-five (85%) of this award will vest on July 16, 2022, and one-seventh of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.
- [F2]On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 22,816 shares of issuer's common stock granted to the Reporting Person on August 11, 2015. In exchange, the Reporting Person received a replacement option for 15,210 shares of issuer's common stock, having an exercise price of $2.44 per share.
- [F3]The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.
- [F4]The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option will vest on December 6, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to Reporting Person continuing to provide service through each such date.
- [F5]On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,632 shares of issuer's common stock granted to the Reporting Person on May 1, 2018. In exchange, the Reporting Person received a replacement option for 12,024 shares of issuer's common stock, having an exercise price of $2.44 per share.
- [F6]The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.
- [F7]The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option shall vest on September 25, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
- [F8]On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 50,411 shares of issuer's common stock granted to the Reporting Person on September 25, 2018. In exchange, the Reporting Person received a replacement option for 28,006 shares of issuer's common stock, having an exercise price of $2.44 per share.
- [F9]Ninety-four (94%) of this award will vest on July 16, 2022, and one-third of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.
Documents
Issuer
Entasis Therapeutics Holdings Inc.
CIK 0001724344
Entity typeother
Related Parties
1- filerCIK 0001751824
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 4:05 PM ET
- Size
- 24.4 KB